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Abstract 
Infections caused by protozoan parasites burden the world with huge costs in terms of human and animal health. 
Most parasitic diseases caused by protozoans are neglected, particularly those associated with poverty and tropical 
countries, but the paucity of drug treatments and vaccines combined with increasing problems of drug resistance are 
becoming major concerns for their control and eradication. In this climate, the discovery/repurposing of new drugs 
and increasing effort in vaccine development should be supplemented with an exploration of new alternative/syn-
ergic treatment strategies. Viruses, either native or engineered, have been employed successfully as highly effective 
and selective therapeutic approaches to treat cancer (oncolytic viruses) and antibiotic-resistant bacterial diseases 
(phage therapy). Increasing evidence is accumulating that many protozoan, but also helminth, parasites harbour a 
range of different classes of viruses that are mostly absent from humans. Although some of these viruses appear to 
have no effect on their parasite hosts, others either have a clear direct negative impact on the parasite or may, in fact, 
contribute to the virulence of parasites for humans. This review will focus mainly on the viruses identified in protozoan 
parasites that are of medical importance. Inspired and informed by the experience gained from the application of 
oncolytic virus- and phage-therapy, rationally-driven strategies to employ these viruses successfully against parasitic 
diseases will be presented and discussed in the light of the current knowledge of the virus biology and the complex 
interplay between the viruses, the parasite hosts and the human host. We also highlight knowledge gaps that should 
be addressed to advance the potential of virotherapy against parasitic diseases.
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Background
According to CDC, “a parasite is an organism that lives 
on or in a host organism and gets its food from or at 
the expense of its host” (https ://www.cdc.gov/paras 
ites/about .html), and for the purposes of this review the 
term parasite will exclusively refer to eukaryotic organ-
isms. Protozoa, together with helminths, represent the 
main cause of parasitic disease in humans in addition 
to livestock and companion animals [1, 2]. Despite the 
great advances in modern medicine, parasitic infections 
continue to burden the world with huge costs in terms 
of human and animal health, and national economies 
directly and indirectly [3]. The prevalence of the major 
human protozoan parasitic diseases (PPDs) is estimated 
to be ca. 790 million individual cases, with a yearly death 
toll of 810,000 and 82.4 million Disability Adjusted Life 
Years (DALY) [4]. Additional indirect negative effects on 
human health can result from zoonotic parasitic infec-
tions [5]. Most PPDs are widely regarded as poverty-
related and as neglected tropical diseases, largely ignored 
for many years by health authorities, pharmaceutical 
Open Access
*Correspondence:  Paul.Barrow@nottingham.ac.uk; marco.lalle@iss.it
1 School of Veterinary Medicine and Science, University of Nottingham, 
Sutton Bonington, Loughborough, Leicestershire LE12 5RD, UK
9 Unit of Foodborne and Neglected Parasitic Diseases, European Union 
Reference Laboratory for Parasites, Department of Infectious Diseases, 
Istituto Superiore Di Sanità, viale Regina Elena 299, 00186 Rome, Italy
Full list of author information is available at the end of the article
Page 2 of 14Barrow et al. Virol J          (2020) 17:142 
companies and the media. It is perhaps not surprising 
that with such a low profile, drugs, vaccines, surveillance 
and control tools are lacking for most of these diseases 
and disease control remains problematic [6–11]. New 
approaches to chemotherapy are needed urgently, involv-
ing combination therapies and other strategies, in addi-
tion to cheaper, less toxic drugs. A paradigm shift is also 
required in the development of chemotherapeutic drugs 
that; (1) target key parasite-specific metabolic path-
ways; (2) do not lead to the development of resistance 
or increase virulence as a result of the parasite genomic 
and metabolic plasticity; (3) are active against dormant 
parasite stages (e.g. Plasmodium vivax hypnozoites, 
Toxoplasma gondii cerebral tissue cysts, etc.); and (4) are 
applicable for asymptomatic cases that act as reservoirs. 
Vaccine development for PPDs remains a serious prob-
lem for several reasons. Host–pathogen interactions are 
generally poorly understood and, in the case of vector-
borne diseases and protozoan parasites, they are com-
plicated by the immune response to insect components 
introduced with the parasite [12]. Protozoan parasites 
are highly efficient at immune escape, with mechanisms 
including (1) antigenic variation, as occurs with Plasmo-
dium, Giardia and the African Trypanosomes [13], (2) 
dormancy and seclusion in safe target tissues, as reported 
for Plasmodium, Toxoplasma and Leishmania [14], (3) 
subversion of host defences reported for Leishmania [15, 
16], (4) capping of host immunoglobulins with protein-
ases as occurs with Trichomonas [17], (5) production 
of anti-apoptotic factors by Cryptospodium [18], or (6) 
down-regulation of host immunity [19]. The use of anti-
microbial peptides, aptamers, nanoparticles, extracellular 
vesicles and natural antimicrobials, including probiotics, 
are currently under investigation to evaluate their feasi-
bility as alternative therapeutic agents, alone or in combi-
nation with chemotherapy [20–23].
To the same end, speculation has begun on the feasibil-
ity of using viruses, in particular those infecting parasites 
[24] for controlling PPDs. The precedent is that bacte-
rial viruses (bacteriophages) and human viruses with 
lytic activity for malignant cells (oncolytic viruses), have 
already been used successfully against antibiotic-resistant 
bacteria and cancers, respectively.
The first clear evidence of viral endosymbionts in para-
sites was the discovery by transmission electron micros-
copy (TEM) of virus-like particles (VLPs) in parasites 
such as the protozoans Entamoeba histolytica and Leish-
mania hertigi (currently Paraleishmania hertigi) [25, 26] 
and the platyhelminth Diplectanum aequans, a parasite 
of fishes [27]. Since then, VLPs and true viruses have 
been documented in a variety of protozoan and helminth 
parasites that in turn parasitize humans, animals, plants 
[28–35], with many more expected to be discovered in 
the near future due to the extensive application of high-
throughput sequence technologies [36].
A complete review of the viruses of protozoan parasites 
is beyond the scope or intention of this review. Rather, 
we will focus mainly on the protozoan parasites Tricho-
monas vaginalis, Leishmania spp., Giardia duodenalis 
and Cryptosporidium spp., and their viral endosymbionts, 
as model systems to present and discuss the potential for 
exploiting their use as native or manipulated viruses to 
treat human parasitic diseases together with the chal-
lenges associated with their application.
Main text
Viral endosymbionts of protozoan parasites
Based on the categorization of virus families by their 
genetic material, mode of replication and structural 
properties, the most extensively characterized viral 
endosymbionts of protozoan parasites of medical rel-
evance are small, non-enveloped, double-stranded (ds) 
RNA viruses of the family Totiviridae [37], with other 
viruses being described including members of the Parti-
tiviridae (non-enveloped dsRNA, bipartite), Narnaviridae 
(uncapsidated, single-stranded positive, ssRNA (+) and, 
monopartite Bunyaviridae (enveloped, single-stranded 
negative, ssRNA (−), tripartite) (Table 1 and Fig. 1).
Within the Totiviridae family, 5 genera, Giardiavirus, 
Trichomonasvirus, Leishmaniavirus, Totivirus, and Vic-
torivirus, are currently recognised which share common 
characteristics [37]. Their genomes are linear uncapped 
dsRNA encoding for two partially overlapping proteins; 
the capsid protein (CP) and the RNA-dependent RNA 
polymerase (RdRp). The RdRp is generally expressed as 
a CP/RdRp fusion protein by means of a − 1 or, more 
rarely, a + 1/− 2 ribosomal frameshift or by ribosomal 
hopping [37]. The viral genome is never found free in 
the protozoan cell and the positive strand viral transcript 
is synthesized within the viral particle by CP/RdRp and 
translocated to the cell cytoplasm to be translated [37]. 
The virions (with a median size of 40 nm) are icosahedral, 
composed of 120 copies of capsid protein with a "T = 2" 
symmetry (alternatively defined as T = 1 icosahedral lat-
tice arranged as 60 asymmetric homodimers) [37, 38].
Trichomonas vaginalis and Trichomonasvirus
The flagellated protozoon Trichomonas vaginalis is 
responsible for 170 million cases/year of trichomo-
niasis, the most common non-viral sexually transmit-
ted infection worldwide [39]. Although asymptomatic 
in males, symptoms of trichomoniasis in women may 
vary from asymptomatic to severe vaginitis, eventu-
ally with pregnancy and postpartum complications [40]. 
The Trichomonas vaginalis virus, TVV, belongs to the 
genus Trichomonasvirus and was the first virus from a 
Page 3 of 14Barrow et al. Virol J          (2020) 17:142  
protozoan parasite to be described and characterised in 
the 1980s, and the first for which the full-length genome 
sequence was reported [41, 42]. Four main phylogeneti-
cally distinct viral species, 1 to 4, have been described, 
with TVV1 closer to TVV2 and TVV3 to TVV4 [43]. 
Diversity exists within each TVV species, with, for exam-
ple, translation of the CP/RdRp fusion protein of TVV1 
involving a -2 ribosomal frameshift unlike TVV2-4 [44, 
45]. Co-infection of a single T. vaginalis with different 
TVV strains has been reported [43]. The TVV infection 
rate among T. vaginalis strains from different geographic 
origins ranges from 40 to 100%, with TVV1 being the 
most commonly detected [46]. TVV seems to be trans-
mitted only vertically, although some studies suggest a 
correlation between specific genetic polymorphisms and 
the entry and multiplication of TVV [42, 44, 47]. The 
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Fig. 1 Protozoan parasites and their viral endosymbionts. The life stages in the human (or mammalian) host of Leishmania spp., Giardia duodenalis, 
Trichomonas vaginalis, Cryptosporidium spp, and Plasmodium spp, are depicted together with a graphical representation of the corresponding 
viral endosymbionts (see also Table 1). Leishmania. Promastigotes, injected in the mammalian host during a sandfly blood-meal, are taken up by 
macrophages in the dermis and quickly surrounded by a parasitophorous vacuole (PV). Promastigotes differentiate into non-motile amastigotes 
and proliferate inside the phagolysosome. Following lysis of infected macrophages, free amastigotes can infect neighbouring macrophages. 
Infected macrophages and/or free amastigotes may then be ingested by sandflies. Giardia. The cyst ingested by the mammalian host releases 
trophozoites that multiply by binary fission and colonize the upper part of the small intestine by adhering to the enterocyte surface. Following 
specific stimuli, trophozoites differentiate back to cysts that are released into the environment in the stool. Trichomonas. Trophozoites are 
transmitted sexually between humans where, by binary fission, they colonize the lower genital tract of females and the urethra and prostate of 
males, No cyst form is known. Cryptosporidium. Oocysts ingested by the mammalian host release sporozoites that invade the epithelial cells 
of the small intestine, form an extra-cytoplasmic yet intra-cellular PV and differentiate into trophozoites. Asexual multiplication by schizogony 
generates meronts that can infect new enterocytes. Eventually trophozoites differentiate into female macrogamonts and male microgamonts. After 
fertilization, the zygote develops into an oocyst that will exit the host through the faeces. Plasmodium. Sporozoites injected in the mammalian host 
during a mosquito blood-meal, invade the hepatocytes, differentiate into trophozoites within a PV and multiply asexually by schizogony giving rise 
to schizont containing many merozoites (hepatic cycle). Hepatic merozoites then invade erythrocytes (RBC) and the schizogonic multiplication 
occurs with newly released merozoites capable of infecting new RBC. Trophozoites in RBC can eventually differentiate in male and female 
gametocytes that will reach mosquitoes during a blood-meal
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presence of TVV influences negatively the growth rate 
of T. vaginalis in vitro if compared to uninfected pro-
tozoan isolates [48] and there is also evidence for lytic 
effects of TVV on T. vaginalis [49]. Almost 50 proteins 
are expressed differentially between TVV-infected and 
uninfected isolates, including metabolic enzymes, heat 
shock proteins (down-regulated in TVV-positive strains), 
and ribosomal proteins (up-regulated in TVV-positive 
strains) [50]. Indeed, infection with TVV increases both 
cytoplasmic and surface expression of the p270 pro-
tein, the major immunogenic protein of T. vaginalis, in a 
phosphorylation-dependent fashion [51]. Similarly, TVV 
infection can modulate the quantitative and qualita-
tive expression of the protozoan cysteine proteases [52]. 
Since cysteine proteases are involved in modulating T. 
vaginalis cyto-adherence to human host cells and in deg-
radation of basement membrane, human cellular mol-
ecules, and secretory IgAs, the viral endosymbiont seems 
to influence and modulate protozoan virulence [52]. A 
correlation between TVV symbiosis with T. vaginalis 
isolates and the severity of clinical symptoms of tricho-
moniasis in humans is emerging; while different papers 
report a positive association between TVV infection 
and the exacerbation of trichomoniasis symptoms, other 
authors have shown the absence of any correlation [53]. 
However, T. vaginalis and its virus appear to have a clear 
role in the subversion of the innate immune response and 
inflammation in the human host [54, 55]. Although TVV 
is unable to infect and replicate in human cells [56], its 
presence can modulate the pro-inflammatory response 
in the human host, amplifying the innate response, and 
thus exacerbating clinical symptoms and the severity 
of disease. The viral dsRNA and TVV particles can be 
sensed by receptors exposed on vaginal cells, triggering 
NF-κB activation via endosomal TLR3/TRIF-dependent 
pathways and leading to expression of Interferon Type 1 
genes [54]. This release of viral dsRNA may be favoured 
by the presence of wide channels in the virion [45]. 
Although the percentage of clinical T. vaginalis isolates 
resistant to 5-nitroimidazole treatment is increasing [57], 
and although a correlation with the presence of TVV has 
been postulated, this is still debated and poorly under-
stood [53, 58, 59]. Paradoxically, in the case of infection 
caused by T. vaginalis carrying TVV, failure of anti-pro-
tozoan therapy with metronidazole in order to prevent 
preterm delivery in pregnant women results in an exacer-
bated inflammatory response explained by the increased 
release of virions and dsRNA as a result of parasite killing 
[45, 60]. The co-existence of dsRNA virus may also dis-
turb the equilibrium of the mucosal microbiome, con-
tributing to its modification in the vagina; infection with 
TVV-positive T. vaginalis isolates indeed promotes vagi-
nal colonization by pathogenic bacteria associated with 
bacterial vaginosis while decreasing the adherence to the 
vaginal epithelium of the major vaginal microflora that 
dominate during eubiosis [42, 54].
Giardia duodenalis and Giardiavirus
The flagellate protozoan parasite G. duodenalis (syn. 
G. lamblia, G. intestinalis) infects the upper intestine 
of humans and other mammals causing giardiasis, a 
zoonotic diarrhoeal disease. The parasite has a global 
distribution with 250–300 million symptomatic human 
infections reported annually, and its impact is more 
pronounced in the developing world and under poor 
socioeconomic conditions [61]. Although self-limiting, 
Giardia infections can become chronic and predispose 
individuals to other chronic gastrointestinal disorders 
such as irritable bowel syndrome (IBS) [62]. Soon after 
the discovery of TVV, the Giardia lamblia virus (GLV) 
was described [63] which is included in the genus Giardi-
avirus together with the virus isolated from the fungus 
Gigaspora margarita [37]. The complete viral genome 
from three isolates is available [64, 65], providing evi-
dence of minimal sequence variability. GLV shows some 
unique characteristics among the Totiviridae: (1) CP 
translation is driven by an unusual Internal Ribosomal 
Entry Site (IRES), spanning the 5′-UTR (untranslated 
region) and the initial portion of the CP coding region 
[66]; (2) the GLV particle is the largest, most robust and 
thermo-stable among Totiviridae allowing extracellular 
horizontal transmission of the virus [67]. Susceptibil-
ity of G. duodenalis to GLV infection has been demon-
strated both by parasite transfection with GLV ssRNA 
and incubation with purified GLV virions, with infected 
parasites being maintained stably over time [68, 69]. GLV 
virus entry is thought to occur via receptor-mediated 
endocytosis since it can be prevented by specific block-
ing agents [70] and not all Giardia isolates are suscepti-
ble to GLV infection [69]. GLV was shown to be unable 
to infect other species of protozoan parasites [59] or to 
induce cytopathic effects in kidney or intestinal mam-
malian cell lines [71, 72]. GLV has been detected, by 
PCR or gel electrophoresis, in more than 30% of G. duo-
denalis isolates belonging to different genetic groups 
(assemblages), both host-specific and zoonotic [73–76]. 
Different cytopathic effects, including growth arrest and 
parasite lysis, have been observed on naïve G. duodenalis 
isolates when first infected with different GLVs purified 
from naturally infected G. duodenalis isolates [63, 73]. 
However, the reported effects could be explained by dif-
ferences in either (1) the amount of virus administered, 
(2) the properties, such as replication efficiency, of each 
virus isolate or (3) variation in parasite susceptibility to 
viral infection [73]. No robust evidence associates GLV 
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infection with resistance to metronidazole, the first-line 
antigiardial drug [77].
Leishmania and Leishmaniaviruses
Different species of the trypanosomatid protozoan Leish-
mania are the causative agents of cutaneous (CL), vis-
ceral (VL) or mucocutaneous (MCL) and disseminated 
(DCL) leishmaniasis, afflicting > 12 million people world-
wide, with 1.2 million new cases/year. The parasites are 
transmitted by phlebotomine sand flies [78, 79]. Within 
Leishmania spp., the Leishmania RNA viruses (LRVs) are 
isolated mainly from the Leishmania Viannia (V.) subge-
nus from South America, and designated LRV1 [80, 81], 
whereas from the old-world Leishmania subgenus (i.e. L. 
aethiopica, L. major and L. tropica) were named LRV2 
[82, 83]. LRV1 and LRV2 genomes differ slightly [84] 
with limited sequence homology of ca. 40% at the pro-
tein level. LRV transmission from one parasite to another 
must occur vertically during cell proliferation, as there is 
no evidence of horizontal transmission. Nevertheless, a 
recent study suggested that LRV particles are also present 
in parasite exosomes which might implicate horizontal 
transmission [85]. Although a systematic review with 
meta-analysis reported a possible estimated prevalence 
of 26%, this value is difficult to be estimated since Leish-
mania parasites have the tendency to lose their LRVs 
endosymbiont in culture [86]. Viral loss possibly relates 
to a burden for parasite replication that in natural con-
ditions is counterbalanced by the selective advantage 
provided by LRV within the sand fly vector, in the mam-
malian host or in both. Supporting this hypothesis LRVs 
are found mainly in Leishmania spp. equipped with RNA 
interference machinery (the system allowing the cell to 
actively recognize and degrade non-self dsRNA, likely to 
be mainly of viral origin) suggesting the importance of 
the parasite’s anti-viral defense in finely balancing viral 
replication rate [87]. Differently from TVV, the presence 
of LRV does not affect parasite growth and there is no 
evidence of modulation of parasite gene expression [88]. 
Despite LRV has been isolated from active and healing 
lesions and scars [89–91], thus far no experimental sys-
tem has allowed long-term maintenance of LRV in Leish-
mania following experimental transfer (N. Fasel personal 
communication). The presence of LRV is reported to sig-
nificantly promote disease relapses in humans infected 
with L. braziliensis, L. guyanensis or L. naiffi and receiv-
ing antimony or pentamidine treatment [92]. MCL, 
characterized by the dissemination of the infection to 
secondary sites with a high inflammatory component, 
has been associated with the presence of LRV in the cyto-
plasm of the parasites [93]. Another striking effect of LRV 
is its impact on treatment failure, while the viral dsRNA 
is also suspected to participate in difficulties in treating 
HIV/L. braziliensis/LRV co-infected patients [94]. How 
LRV impacts drug resistance and relapse is not yet 
known but thanks to the development of different animal 
models a number of mechanisms underlying disease pro-
gression have been identified. Similar to TVV, the pathol-
ogy-exacerbating role of LRV relies on the subversion 
of the host innate immune response, as was shown for 
L. guyanensis or L. aethiopica infection, where the virus 
exacerbates the disease by inducing hyper-inflammation 
and increasing the parasite burden as well as lesion size 
[95, 96]. These phenotypes depend on Toll-like recep-
tor (TLR) 3-mediated recognition of viral dsRNA, which 
leads to the production of Type 1 Interferon (IFN-I), and 
pro-inflammatory cytokines and chemokines [97]. Fur-
thermore, LRV promotes the survival of the mamma-
lian cells infected by Leishmania by phosphorylating the 
AKT1 pro-survival kinase, and favors parasite dissemina-
tion via the induction of IL-17 production [93, 98].
Noteworthy, a tri-segmented linear negative-stranded 
RNA virus (termed, LmarLBV1) with characteristics 
of leishbunyaviruses (an unassigned bunyaviridae-like 
group of viruses) was recently discovered in Leishma-
nia martiniquensis, a protozoan transmitted by bit-
ing midges and responsible for severe visceral disease 
in humans [99]. The presence of LmarLBV1 slightly 
increases the in vitro infectivity of L. martiniquensis on 
primary murine macrophages [99]. Compared to Totivir-
idae, Bunyaviridae have enveloped and spherical virions 
of around 100 nm suggesting that they could be shed by 
L. martiniquensis cells, allowing the virus to interact with 
the immune system of the human host [99].
Other viruses of protozoan parasites of medical relevance
Viruses have been found in other protozoan parasites 
responsible for serious illness in humans, including the 
apicomplexan Cryptosporidium spp. and Plasmodium 
vivax. However, information on the effect of viral infec-
tion on these parasites is fragmentary.
Different species of Cryptosporidium (i.e. C. parvum, 
C. hominis, C felis and C. meleagridis) are pathogenic 
for humans and other vertebrates, and are responsible 
for cryptosporidiosis, a severe diarrhoeal disease caus-
ing death in young children especially in developing 
countries [100]. A bi-segmented dsRNA, termed Cryspo-
virus, of the family Partitiviridae and commonly associ-
ated with plants and fungi, was originally detected in 
C. parvum isolates, and later in other Cryptosporidium 
spp.[101, 102]. The dsRNA segments 1 (1.8  Kb) and 2 
(1.4 Kb), likely uncapped and not polyadenylated, encode 
the RdRp and CP, respectively. The isometric virion is 
composed of 120 subunits (T = 1) of the 37 kDa CP, the 
smallest capsid protein known among Partitiviridae 
with each viral genome segment encapsidated separately 
Page 7 of 14Barrow et al. Virol J          (2020) 17:142  
[102]. As with other partitiviruses, CspV1 is thought to 
be transmitted intracellularly, being present in the envi-
ronmentally resistant oocyst stage, although recent 
observation suggests that CspV1 is also released into 
the medium early in the parasite infection of the human 
host cell [103]. Based on dsRNA2 sequence comparison, 
a greater divergence exists between CSpV1 and viruses 
from C. hominis, C. felis and C. meleagridis, suggesting 
that the virus might have a certain degree of host-speci-
ficity and, therefore, the existence of more than one spe-
cies in the genus Cryspovirus [104]. Infection by CSpV1 is 
commonly detected in field and clinical isolates of C. par-
vum [105]. A correlation between CSpV1 dsRNA2 levels 
and C. parvum fecundity has been reported in culture 
models, where higher level of the viral symbiont are asso-
ciated with greater parasite multiplication [106]. How-
ever, no information on infection in an animal model is 
available.
Six Plasmodium spp. (P. falciparum, P. vivax, P. malar-
iae, P. ovale curtisi, P. ovale wallikeri, and P. knowlesi) 
infect humans, transmitted by the bite of an infected 
female Anopheles mosquito, and are responsible for 
malaria, the most important PPD affecting humans, 
with an incidence of more than 200 million case/year 
and 400 thousand deaths/year [107]. A bi-segmented 
narna-like ssRNA (+) virus has been very recently iso-
lated only from P. vivax and named Matryoshka (after 
the Russian dolls) RNA virus 1 (MaRNAV-1) [33], show-
ing high homology to the monopartite, linear, positive 
sense (ss)RNA narnaviruses found in fungi, plants and 
other protists. The trypanosomatid Leptomonas sey-
mouri, transmitted by the sandfly vector, as is Leishmania 
donovani, can also harbour a symbiotic narna-like virus 
(LepsyNLV1) [108]. It is noteworthy that severe cases of 
visceral leishmaniasis in India have been associated to 
co-infection with by L. donovani and a narna-like posi-
tive L. seymouri [109].
What can we learn from approved viral therapies; bacterial 
viruses (bacteriophage) and oncolytic viruses?
Viruses are already in use in medicine, the two best-
known examples being bacterial viruses (bacteriophages, 
phages) to treat bacterial infections and oncolytic viruses 
(OVs) in the treatment of cancer [110].
The specificity of bacteriophages, absence of adverse 
effects on the normal bacterial flora (unlike antibiotics), 
their greater efficacy than some antibiotics [111] and lit-
tle evidence of them causing harm on administration are 
major advantages for their application. However, bacteri-
ophages as a generic group are not yet considered to have 
a qualified presumption of safety (QPS) by the EU [112] 
although they have been used several times in the US for 
untreatable infections [113].
Their successful use to control and prevent a variety of 
bacterial infections is based on their lytic activity but is 
conditional on their use under carefully controlled condi-
tions. These include phage preparation according to good 
manufacturing practices, demonstration of phage efficacy 
and safety in randomized controlled trials and marketing 
authorization. Indeed, the evidence for their efficacy is 
a combination of (1) a huge number of individual treat-
ments in Eastern European countries involving different 
bacterial infections, (2) highly controlled experimental 
infections using animal models of enteritis, septicae-
mia, superficial burns and other types of infections, and 
(3) much earlier trials carried out in the 1920s–1930s 
some of which, admittedly, were criticised for their poor 
scientific quality [114, 115]. In the fight against anti-
biotic resistance (AMR), phages specific for the sex pili 
produced by self-transmissible AMR plasmids can be 
employed for the replacement of an AMR strain by an 
antibiotic-sensitive derivative in a bacterial population 
[116]. This is a good example of how the complex evolu-
tionary relationship between a virus and its host (i.e. bac-
teria, bacteriophage and self-transmissible plasmids) can 
be used to our advantage.
It should, however, be noted that some phages are able 
to transfer bacterial genes by transduction, a factor that 
must be taken into consideration during the early stage 
of phage selection. A comprehensive analysis of theoreti-
cal advantages of phages over antibiotics, together with 
some of their limitations, has been reviewed [117, 118] 
including the degree of synergy with antibiotics. How-
ever, phage-bacterial co-evolution is of immediate prac-
tical significance to phage therapy in the development 
of bacterial resistance to the phage during treatment. 
Several strategies have been used to overcome this issue 
[117], including: (1) the use of two phages, one of which 
targets the original bacteria and the second of which tar-
gets the phage-resistant mutants that arise in response 
to the first phage [111], and (2) selecting phages that tar-
get surface virulence determinants so that most phage- 
resistant mutants are attenuated and thus do not produce 
disease [111]. Interestingly, in the case of the use of phage 
against the pili produced by AMR bacteria, the selec-
tion of phage-resistant mutants is desired. In addition to 
exploitation of their lytic activity, phages have been also 
manipulated to deliver toxin genes into pathogens as an 
alternative to chemotherapy [119], or to deliver a func-
tional CRISPR-Cas system destroying antibiotic resist-
ance plasmids [120, 121]. However, despite their great 
promise, reasons for the slow adoption of phages in 
human medicine and the paucity of randomised, double 
blind trials [122–124] can be found, among others, in the 
difficulties with intellectual property and registration, 
some of which may be overcome by the use of magistral 
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(personalised) phages [125] for treatment of individual 
infections.
A variety of human and animal viruses have been tested 
for their application as oncolytic viruses (OVs) including 
herpes viruses, pox viruses, the Edmonton strain of Mea-
sles virus and, most frequently, adenoviruses since they 
have few side effects and their genomes are easily manip-
ulated. The ability of viruses to target cancer cells arises 
from their exploitation of the aberrant signaling path-
ways and the generally poor antiviral response produced 
by cancer cells [126].
Many viruses are able to induce lysis of cancer cells 
in  vitro but their effect in  vivo appears primarily to 
involve modification of the micro- and macro-envi-
ronment of the tumor with the induction of apoptotic 
pathways and stimulation of innate immunity by TLR 
activation [127]. Contact between cancer cells and virus 
triggers a stress response involving reactive oxygen spe-
cies (ROS) and release of Damage-Associated Molecular 
Patterns (DAMPs), also initiating an immune response 
[128]. Although OVs lyse a variety of cell types in vitro, 
the outcomes of their clinical use are enhanced by com-
bination with other treatments, such as immune therapy 
[129] or general or targeted chemotherapy [130] for a 
wide range of cancer types [126].
Oncolytic viruses (OVs) have been transformed from 
the object of laboratory studies [126] to full scale clinical 
trials with the acceptance of three OVs for full clinical use 
[126]. A non-pathogenic ECHO virus has been registered 
for use in several Eastern European countries, an attenu-
ated adenovirus has been registered for use in China and 
a modified herpes virus (HSV-1) was approved by the 
FDA and EMA in 2015 and is now used routinely for cer-
tain melanomas [126].
OV therapy has a number of advantages over current 
antitumor therapies. OVs can selectively replicate in 
tumor cells [127] and can act as vectors for therapeutic 
and immune-stimulatory genes [132] for specific expres-
sion at tumor sites [133]. Some OVs are reported to cross 
the blood–brain barrier and they can increase the sen-
sitivity of cancer cells to other immune-therapies. Inter-
estingly, and, unlike bacteriophages, resistance to the 
viruses has not so far been observed. In theory, and simi-
larly to bacteriophages, virus dose in the tumor increases 
as a result of in situ virus amplification that is different to 
normal drug pharmacokinetics [127].
The general safety of oncolytic viral therapy has been 
highlighted by published clinical trials, although some 
aspects, including off-target effects, unexpected toxic 
effects as result of the viral genome manipulation, virus 
mutation, evolution, and recombination, remain a theo-
retical concern [134]. Other potential limitations relate 
to the requirement of the viruses to reach every cell in 
the tumor and to spread between the tumor cells and the 
occurrence of neutralizing antibodies in the host that 
could result in a rapid shut down of viral replication. By 
the incorporation of biological markers in OVs they can 
also play an integral role of tumor visualization [135].
Exploitation of viruses of protozoan parasites–scope 
for therapy
The experience with oncolytic viruses and bacteriophages 
suggests that parasite viruses may be used in a variety of 
ways, including via their own lytic activity, possibly syn-
ergistically with other approaches to treatment includ-
ing immunotherapy and chemotherapy, for drug delivery 
using virus-like particles (VLPs) and also by manipulat-
ing their genomes for specific purposes.
Application of viruses by their direct parasitopathic activity
To maximize any parasitopathic activity of a viral sym-
biont, the selectivity of the virus toward the right para-
site target must be high. This seems to not be an issue, at 
least for GLV, TVV and LRV viruses [56, 63]. Moreover, 
replication of the virus should be maximal at the most 
appropriate parasite stage infecting the human (or ani-
mal) host. For those protozoan parasites with relatively 
simple life cycles, such has Giardia, Cryptosporidium and 
Trichomonas, with parasite multiplication occurring pre-
dominantly in one site (e.g. gastrointestinal epithelium 
for Giardia and Cryptosporidium, vaginal epithelium for 
Trichomonas) within the final human (or animal) host, 
the endosymbiont virus is likely to replicate maximally 
where the parasite is also multiplying (e.g. trophozoite 
for Giardia and Trichomonas, amastigote for Leishma-
nia, merozoite for Cryptosporidium) (Fig. 1). The picture 
is likely to be more complex when different replication 
stages occur during the parasite life cycle, as for Leishma-
nia and Plasmodium, for instance, and in more than one 
host (i.e. intermediate and definitive hosts) in addition to 
multiple sites (tissues or organs) in the same host (Fig. 1). 
Thus, viruses that multiply optimally in one phase of 
the life cycle might, nevertheless, be used profitably for 
infection control in another. These speculations remain 
to be tested. The extent to which the viruses might be 
used alone or synergistically also remains to be assessed.
Such use of wild-type viral symbionts seems, at the 
moment, to be applicable only to Giardia (at least for 
some parasite isolates) where parasite overload with GLV 
causes cell growth arrest, and likely cell death [63, 73]. Of 
course, for this kind of strategy some key aspects must 
be taken into account, such as: (1) an efficient cell factory 
for high titre virus production; (2) pharmaceutical grade 
purification of the viral particles for treatment use, and 
(3) a successful delivery system for the administration of 
the viral dose to the patient. Problems associated with 
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human (or animal) immune response to the viral admin-
istration must of course be evaluated in advance. It is evi-
dent that TVV and LRV might be disadvantaged in this 
specific issue due to their adverse impact on the human 
immune system [54, 55, 95].
Use of VLPs for chemotherapy
An alternative to using infectious viruses to attack par-
asites, is their use as VLPs to deliver toxic antiparasitic 
agents to the parasite host cells. VLPs consist of the 
assembled viral coat protein subunits that provide empty 
viral shells which can be loaded with the desired mate-
rial. The outer surface can also be decorated with target-
ing moieties, either genetically or chemically. VLPs based 
on plant viruses have been exploited particularly for this 
application as they can be produced in large quantities, 
are stable and can often be readily disassembled and 
reassembled in  vitro to allow the incorporation of drug 
molecules [136–138].
To date, much of the research on the use of VLPs has 
concentrated on delivering drugs for anti-cancer therapy 
[139–142]. However, there has been increasing interest 
in using VLPs to deliver agricultural pesticides to combat 
plant-parasitic nematodes [143, 144]. The encapsulation 
of nematicides within VLPs increases their mobility and 
persistence, although the effect varies with the nature 
of the VLP [143, 144]. These recent results indicate that 
drug delivery via VLPs may be an effective way of treat-
ing parasites other than those of plants. Of particular 
concern in anti-parasitic drug therapy in humans and 
animals is, for example, the low bioavailability (e.g. poor 
bioavailability of benzimidazoles) or the off-target effect 
(e.g. nitroimidazoles also targeting commensal anaerobic 
bacteria in the intestine) of certain drugs [62, 146] Use of 
VLP delivery could indeed help to overcome such unde-
sired limitations thus improving treatment quality and 
increasing drug efficacy. Indeed, the viral particles would 
be depleted of their nucleic acid content and, in the case 
of TTV and LRV, this would avoid adverse human host 
response to the viral dsRNA release [54, 95]. Among the 
obstacles in production of VLP for therapeutic purposes 
are, in addition to those for preparation of wild-type 
virus, the need to express at high yield the sole protein(s) 
constituting the capsid and guaranteeing the correct 
assembly of the viral particles, likely in an appropriate 
heterologous biological system, in addition to efficiently 
loading the antiparasitic agent.
The potential use of the viral symbiont for molecular 
manipulation of the parasite host
Several technical approaches may be contemplated for 
the delivery of nucleic acid sequences that will interrupt 
parasite physiology or kill the parasite. The introduction 
of antisense sequences to block translation of key genes 
has been discussed for modulating bacterial physiology 
but is thought to be less effective and not as easy as origi-
nally thought [147], with tRNA processing with external 
guide sequences as an example [148]. For instance, mor-
pholinos (DNA oligomers modified with methylenemor-
pholine rings) have been used successfully for transient 
knock-down of essential genes in Giardia and Crypto-
sporidium [149, 150]. Other approaches could be used 
to target genes directly with key function(s) for parasite 
survival. More recently, the CRISPR-Cas system has been 
used increasingly for making targeted mutations being 
successful also in Giardia, Plasmodium, Trichomonas 
and Leishmania [151–154]. The system uses guide RNAs 
to direct a DNA nuclease complex to a target sequence 
by complementarity with the guide DNA. This has been 
modified by using dCas9 which is a double nuclease 
active-site mutant that binds to the DNA target selec-
tively, in this case leading not to cleavage but to inhibi-
tion of RNA polymerase initiation and elongation [155]. 
However, antisense molecules and gene-editing systems 
do not readily cross cell membranes limiting their use in 
in  vitro systems where techniques, such as electropora-
tion, have been developed to introduce the molecules 
into cells. VLPs could, indeed, be very useful for their 
delivery in vivo. An example of such use of the viral sym-
biont is represented by engineered GLV to express ham-
merhead ribozymes [156]. The use of catalytic ribozymes 
[157] to inactivate target genes is a good example but it 
may be dependent on the relative transcription rates of 
the genes involved and may also be affected by poor turn-
over rates under physiological conditions. In Giardia, 
this approach has been successful to knock down specific 
genes and also provided evidence for the possibility of 
combining gene silencing by virus-mediated hammer-
head ribozymes with chemotherapy [156]. However, this 
approach always requires co-infection with a replication-
competent helper virus.
Further strategies to engineered VLP of viral symbionts 
of parasites could, of course, be explored to improve gene 
delivery to different parasites, as exemplified by the use 
of engineered bacteriophage T4 expressing antigens facil-
itating specific cell targeting [120].
Conclusion
The endosymbiont viruses of protozoan parasites are 
a relatively new but rapidly expanding field of research. 
However, when compared to the use of bacteriophage 
and oncolytic viruses more pure and applied research 
will be needed before their use can be contemplated 
against protozoan parasite infections in human medicine. 
In accord with recent efforts to establish a platform to 
explore and understand the parasite microbiome through 
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an integrated approach [158], we advocate intensification 
of the research in this area both from the point of view 
of basic biology but also in areas pertinent to infectious 
disease including epidemiology and the potential for dis-
ease treatment and prophylaxis. Both in vivo and in vitro 
infection models will be required to study virus-parasite 
interactions both independently and in association with 
the human or animal hosts of the parasites [159]. Due 
to their complex life cycles and culture requirements, 
for many protozoan parasites such models are still inad-
equate, incomplete, since they do not replicate all the 
parasite life stages, do not exist, or might simply not be 
suited to evaluating virus behaviour [160–163].
We believe that the time is right to begin a more thor-
ough investigation into viruses of protozoan parasites 
with a view to evaluating them as agents for controlling 
the many largely intractable infections that they produce.
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